259 related articles for article (PubMed ID: 19270218)
1. Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?
Bozkurt D; Hur E; Ulkuden B; Sezak M; Nar H; Purclutepe O; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S202-5. PubMed ID: 19270218
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
3. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
4. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis.
Bozkurt D; Cetin P; Sipahi S; Hur E; Nar H; Ertilav M; Sezak M; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S38-42. PubMed ID: 19008539
[TBL] [Abstract][Full Text] [Related]
5. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis.
Bozkurt D; Bicak S; Sipahi S; Taskin H; Hur E; Ertilav M; Sen S; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S53-7. PubMed ID: 19008543
[TBL] [Abstract][Full Text] [Related]
6. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis?
Bozkurt D; Sipahi S; Cetin P; Hur E; Ozdemir O; Ertilav M; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S206-10. PubMed ID: 19270219
[TBL] [Abstract][Full Text] [Related]
7. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
[TBL] [Abstract][Full Text] [Related]
8. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats.
Hur E; Bozkurt D; Timur O; Bicak S; Sarsik B; Akcicek F; Duman S
Clin Nephrol; 2012 Jan; 77(1):1-7. PubMed ID: 22185962
[TBL] [Abstract][Full Text] [Related]
9. Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.
Velioglu A; Tugtepe H; Asicioglu E; Yilmaz N; Filinte D; Arikan H; Koc M; Tuglular S; Kaya H; Ozener C
Ren Fail; 2013; 35(4):531-7. PubMed ID: 23473055
[TBL] [Abstract][Full Text] [Related]
10. Role of adhesion molecules in the progression of peritoneal sclerosis.
Imai H; Nakamoto H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
Adv Perit Dial; 2003; 19():180-5. PubMed ID: 14763058
[TBL] [Abstract][Full Text] [Related]
11. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Nakamoto H; Imai H; Fukushima R; Ishida Y; Yamanouchi Y; Suzuki H
Perit Dial Int; 2008 Jun; 28 Suppl 3():S83-7. PubMed ID: 18552271
[TBL] [Abstract][Full Text] [Related]
12. A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.
Bozkurt D; Sarsik B; Hur E; Ertilav M; Karaca B; Timur O; Bicak S; Akcicek F; Duman S
J Nephrol; 2011; 24(3):359-65. PubMed ID: 21240876
[TBL] [Abstract][Full Text] [Related]
13. By reducing production of vascular endothelial growth factor octreotide improves the peritoneal vascular alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Akpolat N; Ustündag B; Duman S; Akcicek F
Perit Dial Int; 2002; 22(3):301-6. PubMed ID: 12227386
[TBL] [Abstract][Full Text] [Related]
14. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?
Duman S; Günal AI; Sen S; Asçi G; Ozkahya M; Terzioglu E; Akçiçek F; Atabay G
Perit Dial Int; 2001; 21(2):219-24. PubMed ID: 11330572
[TBL] [Abstract][Full Text] [Related]
15. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
16. N-Acetylcysteine protects the peritoneum from the injury induced by hypertonic dialysis solution.
Bui DS; Seguro AC; Shimitzu MH; Schliemann I; Martini D; Romão JE; Pecoits Filho RF; Abensur H
J Nephrol; 2012; 25(1):90-5. PubMed ID: 21667456
[TBL] [Abstract][Full Text] [Related]
17. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats.
Duman S; Sen S; Duman C; Oreopoulos DG
Int J Artif Organs; 2005 Feb; 28(2):156-63. PubMed ID: 15770604
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin suppresses peritoneal fibrosis in rat experimental model.
Mondello S; Mazzon E; Di Paola R; Crisafulli C; Italiano D; Buemi M; Aloisi C; Cuzzocrea S
Eur J Pharmacol; 2009 Feb; 604(1-3):138-49. PubMed ID: 19073168
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat.
Park SH; Lee EG; Kim IS; Kim YJ; Cho DK; Kim YL
Perit Dial Int; 2004; 24(2):115-22. PubMed ID: 15119632
[TBL] [Abstract][Full Text] [Related]
20. New animal models for encapsulating peritoneal sclerosis--role of acidic solution.
Nakamoto H; Imai H; Ishida Y; Yamanouchi Y; Inoue T; Okada H; Suzuki H
Perit Dial Int; 2001; 21 Suppl 3():S349-53. PubMed ID: 11887851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
